medigraphic.com

1999, Número 4

<< Anterior

Enf Infec Microbiol 1999; 19 (4)


Decisiones de manejo de la neumonía adquirida en la comunidad (NAC)
Avances en el tratamiento antimicrobiano de la neumonía adquirida en la comunidad
Profilaxis con fluconazol semanal vs diario para infecciones fúngicas en pacientes con SIDA
Comentario editorial: profilaxis antifúngica con fluconazol semanal para pacientes con SIDA
Comparación de itraconazol vs fluconazol como tratamiento de mantenimiento para la meningitis criptocócica relacionada con el SIDA
Comentario editorial: comparación de itraconazol vs fluconazol como tratamiento de mantenimiento para la meningitis criptocócica relacionada con el SIDA
Los antibióticos no tienen efecto en la diarrea e incrementan la recidiva bacteriológica en la infección intestinal por Salmonella
La terapéutica dual no mantiene la supresión de la replicación viral en la infección por el HIV-1

Marri TJ, Mandell LA, Havlir DV, Dubé MP, McCutchan JA, Mylonakis E, Flanigan TP, Saag MS, Cloud GA, Graybill JR, Larsen RA, Sirinavin S, Garner P, Reijers MH, Weverling GJ, Jurriaans S

Idioma: Español
Referencias bibliográficas: 127
Paginas: 199-218
Archivo PDF: 111.27 Kb.


FRAGMENTO

El tratamiento exitoso de la neumonía adquirida en la comunidad requiere muchas decisiones de manejo, incluyendo el sitio de atención, el tipo y duración del tratamiento antibiótico y el alta de los pacientes que requieren hospitalización.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Centers for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contacts-United States. MMWR 1997;46:556.

  2. Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB, Breiman RF. Incidence of community-acquired pneumonia requiring hospitalization: Results of a populationbased active surveillance study in Ohio. Arch Intern Med 1997;157:1709-18.

  3. Coley CM, Li YH, Medsger AR, Marrie TJ, Fine MJ, Kapoor WN, et al. Preferences for home vs hospital care among low risk patients with community-acquired pneumonia. Arch Intern Med 1996;156:1565-71.

  4. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:143-50.

  5. Atlas SJ, Benzer TI, Borowsky LH, Chang YC, Bumham DC, Metlay JP, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients. Arch Intern Med 1998;158:1350-6.

  6. Marrie T, Lau C, Feagan B, Wheeler S, Wong C. For the capital study investigators and Janssen-Ortho Inc., Canada, 1998. A randomized controlled trial of a critical pathway for the management of community-acquired pneumonia. Sixth International Quinolone Meeting; Denver, CO, 16-18 November, 1998.

  7. Niederman MS, Best JB, Campbell GD, Fein AM, Grossman RF, Mendell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.

  8. Ewig S, Ruiz M, Mensa J, Marcos MA, Martínez JA, Arancibia F, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8.

  9. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4.

  10. Ramírez JA, Srinath L, Ankee S, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155-1273-6.

  11. Ramírez JA, Ankee S. Early switch from intravenous antimicrobial to oral clarithromycin in patients with communityacquired pneumonia. Infect Med 1997;14:319-23.

  12. Ramírez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med 1995;2:327-33.

  13. Fine MJ, Medsger AR, Stone RA, Marrie TJ, Coley CM, Singer DE, et al. The hospital discharge decision for patients with community-acquired pneumonia. Results from the pneumonia patient outcomes research team cohort study. Arch Intern Med 1997;157:47-56.

  14. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia. Implications for practice guidelines. JAMA 1998;279:1452-7.

  15. Selker HP, Beshansky JR, Pauker SG, Kassirer JP. The epidemiology of delays in a teaching hospital. The development and use of a tool that detects unnecessary hospital days. Med Care 1989;27;112-22.

  16. Calkins DR, Davis RB, Reiley P, Phillips RS, Pineo KLC, Delbanco TL, Iezzoni LI. Patient-physician communication at hospital discharge and patients’ understanding of the postdischarge treatment plan. Arch Intern Med 1997;157:1026- 30.

  17. Mandell LA, Niederman M. The Canadian community-acquired pneumonia consensus conference group: Antimicrobial treatment of community-acquired pneumonia in adults: A conference report. Can J Infect Dis 1993;4:25-28.

  18. Niederman MS, Bass JB, Campbell GD, Fein AM, Grossman RF, Mandell LA. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. 1993;148:1418-26.

  19. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Communityacquired pneumonia in adults: Guidelines for management. Clin Infect Dis 1998;26:811-38.

  20. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78:45-51.

  21. National Center for Health Statistics. National hospital discharge survey: Annual summary 1990; Vital Health Stat 1992;13:1- 225.

  22. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with communityacquired pneumonia. Infect Dis Clin North Am 1998;12:741-59.

  23. Mandell LA, Loeb M. Microbiology of hospital-acquired pneumonia. Semin Respir Crit Care Med 1997;18:111-20.

  24. Bartlett JG, O’Keefe P, Talley F, Louie TJ, Gorbach SL, et al. Bacteriology of hospital-acquired pneumonia. Arch Intern Med 1986;146:868-71.

  25. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study f 359 cases. Medicine 1990;69:307-16.

  26. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994;18:501-15.

  27. Marston BJ, Plouffe JF, File Jr TM, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio. Arch Intern Med 1997;157:1709-18.

  28. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankly SS, Weissfeld, et al. Prognosis and outcomes of patients with communityacquired pneumonia. JAMA 1996;275:141-3.

  29. Berntsson E, Lagergard T, Strannegard O, Trollfors B, et al. Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol 1996;5:446.

  30. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN, et al. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 1996;101:508.

  31. Erard PH, Moser F, Wenger A, Saghafi L, Bille J, Francioli P, et al. Prospective study on community-acquired pneumonia diagnosed and followed up by private practitioners. CHUV, Laussane, Switzerland. Abstracts of the 31st ICAAC, Chicago, IL. October 1991. Abstract 56.

  32. Langille DB, Yates L, Marrie TJ. Serological investigation of pneumonia as it presents to the physician’s office. Can J Infect Dis 1993;4:328-32.

  33. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia: Etiology, epidemiology and prognostic factors. Chest 1994;105:1487-95.

  34. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia: Etiology, prognosis and treatment. Am Rev Respir Dis 1990;142:369-73.

  35. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S5 supplement, vol. 24, no. 16. Villanova, PA: National Committee for Laboratory Standards:1994.

  36. Doern GV, Brueggemann A, Holley Jr HP, Doern GV, Brueggemann A, Holley HP Jr., Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agentes Chemother 1996;40:1208-13.

  37. Einarsson S, Kristjansson M, Kristinsson K, Kjartansson G, Johnsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study. Scand J Infect Dis 1998;30:253-6.

  38. Klugman KP, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia. Infect Dis Pract 1998;7:180-4.

  39. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.

  40. Plouffe JF, Breiman RF, Facklam RR for the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. JAMA 1996;275:194-8.

  41. Wise R, Brenwald N, Gill M, Fraise A. Streptococcus pneumoniae resistance to fluoroquinolones [Letter]. Lancet 1996;348:1660.

  42. Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JM, Beaucaire G. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intens Care Med 1995;21:24-31.

  43. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterial. J Antimicrob Chemother 1994;33:685-706.

  44. Dalhoff A, petersen U, Endermann R. In vitro activity of BAY 12- 8039, a new 8-methoxyquinolone. Chemotherapy 1996;42:410- 25.

  45. Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ. In vivo activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother 1997;40:205-11.

  46. Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Gruneberg RN. In vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997;39(Suppl B):39-43.

  47. Biedenbach DJ, Jones RN. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis 1996;25:47-51.

  48. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:478-80.

  49. Shonekan D, Handwerger S, Mildvan D. Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, cinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother 1997;39:405-9.

  50. Bauernfeind A. Comparative in vitro activities of the new quinolone, Bay 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother 1993;31:505-22.

  51. Wiedemann B, Heisig P. Antibacterial activity of grepafloxacin. J Antimicrob Chemother 1997;40(Suppl A):19-25.

  52. Wise R, Andres JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother 1997;40(Suppl A):27-30.

  53. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and resistant pneumococci [Letter]. J Antimicrob Chemother 1995;35:230-2.

  54. Fass RJ. In vitro activity of Bay 12-8039, a new 8- methoxyquinolone. Antimicrob Agents Chemother 1997;41: 1818-24.

  55. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997;41:101-6.

  56. Rolston KVI, Ho DH, Leblanc B, Streeter H, Dvorak T. In vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother 1997;39(Suppl B):15-22.

  57. Hoska M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992;36:2108-17.

  58. Wise R, Brenwald NP, Andrews JM, Boswell F. The activity of the methylpiperazinyl fluoroquinolone CG 5501: A comparison with other fluoroquinolones. J Antimicrob Chemother 1997;39:447-52.

  59. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. J Antimicrob Chemother 1997;41:2312-6.

  60. Aldridge KE, Ashcraft D, Bowman KA. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother 1997;41:484-7.

  61. Nord CE. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis 1996;23(Suppl 1):S15-S18.

  62. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillintazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994;38:2471-6.

  63. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobial against clinically important anaerobes. Antimicrob Agents Chemother 1997;41:709-11.

  64. Goldstein EJC, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-990, and WN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992;36:1158-62.

  65. Appelbaum PC. Quinolone activity against anaerobes: Microbiological aspects. Drugs 1995;49(Suppl 2):76-80.

  66. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996;23(Suppl 1):S2-S8.

  67. Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolones, against Chlamydia spp. Antimicrob Agents Chemother 1997;41:1331-4.

  68. Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to parfloxacin and PD 127391. Antimicrob Agents Chemother 1991;35:1181-5.

  69. Ridgway GL, Salman H, Robbins MJ, Dencer C, Flemingham D. The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997;40(Suppl A):31-34.

  70. Edelstein PH, Edelstein MAC, Lehr KH, Ren J. In vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumonia. J Antimicrob Chemother 1996;37:117- 28.

  71. Kaku M, Ishida K, Irifune K, et al. In vitro an in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:738-41.

  72. Roblin PM, Hammerschlag MR. Activity of BAY 12-8039, a new 8-methoxyquinolone, against Chlamydia pneumoniae in vitro (Abstract F011). In: Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans: American Society of Microbiology, 1996:101.

  73. Roblin PM, Jutline A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997;41:2033-4.

  74. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumonia, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996;40:1048-9.

  75. Craig WA. Pharmacokinetic/pharmacodynamic parameters. Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.

  76. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998;27:33-39.

  77. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: Application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-26.

  78. Blaser J, Stone BB, Groner M, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.

  79. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989;159:281-92.

  80. Drussano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90.

  81. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.

  82. Preston SL, Drussano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA 1995;279:125-9. MANDELL LA

  83. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Resp J 1995;8:1999-2007.

  84. Örtqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C, and the Scandinavian Sparfloxacin Study Group. Oral empiric treatment of community-acquired pneumonia. Chest 1996;110:1499-506.

  85. Portier H, May T, Proust A, and the French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37(Suppl A):83-91.

  86. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB, and the Sparfloxacin European Study Group. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of communityacquired suspected pneumococcal pneumonia in adults. Clin Infect Dis 1996;26:1312-20.

  87. O’Doherty B, Dutchman DA, Pettie R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997;40(Suppl A):73-81.

  88. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrobia 1997;41: 1965-72.

  89. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: Treatment issues. Clin Infect Dis 1998;26:259-72.

  90. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: Three San Francisco epidemiological cohorts. AIDS 1991;5:519- 25.

  91. Ferreira S, Cardoso AS, Silva A Jr., Oliveria AM, Reixoto CA. Oral manifestations in HIV/AIDS patients under antiretroviral therapy. [Abstract no. 24374]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:511.

  92. Rex JH, Rinaldi MG, Pfaller MA. Resistance to Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.

  93. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19:684-6.

  94. Freedberg KA, Scharfstein JA, Seage GR, et al. The costeffectiveness of preventing AIDS-related opportunistic infections. JAMA 1998;279:130-6.

  95. Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 1996;26:186-7.

  96. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trial Group. N Engl J Med 1995;332:700-5.

  97. Anonymous. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group MMWR Morb Mortal Wkly Rep 1997;46(RR-12):1-46.

  98. Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22(suppl 2):S119-S123.

  99. Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: Prevention issues and priorities. Clin Infect Dis 1995;21(suppl 1):S99-S102.

  100. Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: A doubleblind placebo-controlled study. J Infect 1990;21:55-60.

  101. Marriott DJ, Jones PD, Hoy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients: A doubleblind placebo-controlled study. Med J Aust 1993;158:312-6.

  102. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997;126:689-96.

  103. Havlir DV, Dubé MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998;27:1369-75.

  104. Gardino J, Kaiser L, Auckentaler A, Geneva V, Hirschel B. Introduction of proteinase inhibitors results in decreasing incidence of oropharyngeal candidiasis in an HIV patient cohort study [abstract no. 22221]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:306.

  105. Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors [letter]. AIDS 1998;12:447-8.

  106. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir [letter]. N Engl J Med 1996;334:1674-5.

  107. Cassone A, Adriani D, Tacconelli E, Cauda R, De Bernardis F. HIV protease inhibitors have a direct anti-Candida effect by inhibition of Candida aspartyl proteinase [abstract no. 31211]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:537.

  108. Mastroianni CM, Mengoni F, Lichtner M, et al. Effect of highly active antiretroviral treatment (HAART) on neutrophil and monocyte function [abstract no. 12322]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:77.

  109. Quagliarello VJ, Viscoli C, Horwitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995;345:548-52.

  110. Manfredi R, Mastroianni A, Coronado OV, Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997;157:64-69.

  111. Newton JA Jr., Tasker SA, Bone WD, et al. Weekly fluconazole for the suppression of recurrent thrush on HIV-seropositive patients: Impact on the incidence of disseminated cryptococcal infection [letter]. AIDS 1995;9:1286-7.

  112. Nelson MR, Fisher M, Cartledge J, Rogers T, Gazzard BG. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994;8:651-4.

  113. White A, Goetz MB. Azole-resistant Candida albicans: Report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994;19:687-92.

  114. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.

  115. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.

  116. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999;28:291-6.

  117. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8.

  118. Bozzette SA, Larsen RA, Chiu J, et al. A placebo controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 199;324:580-4.

  119. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDSassociated cryptococcal meningitis. N Engl J Med 1992;326:83- 9.

  120. Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 1989;11:125- 8.

  121. Bozzette SA, Larsen RA, Chiu J, et al. Fluconazole treatment of perssistent Cryptococcus neoformans prostatic infection in AIDS. Ann Intern Med 1991;115:285-6.

  122. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: A randomized trial. Ann Intern Med 1990;113:183-7.

  123. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5.

  124. Dismukes WE, Cloud GA, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-41.

  125. Goodman LJ, Trenholme GM, Kaplan RL, et al. Arch Intern Med 1990;150:541-6.

  126. Raffi F, Pialoux C, Brun-Vezinet F, et al. Results of TRILEGE trial, a comparison of three maintenance regimens for HIV infected adults receiving induction therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). Fifth National Conference on Retroviruses and Opportunistic Infections, Chicago, USA, February 1-5, 1998:LB15 (abstract).

  127. Havlir DV, Marschner IC, Hirsch M, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HI RNA after triple-drug therapy. N Engl J Med 1998;339:1261-8.




2020     |     www.medigraphic.com